Browsing Tag
breast cancer treatment
15 posts
Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have…
Breakthrough in breast cancer treatment? BriaCell Therapeutics shares soar 150%!
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following…
Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment
Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a…
Hinova Pharmaceuticals’ HP518 gets FDA fast track designation in triple-negative breast cancer
Hinova Pharmaceuticals Inc. (688302.SH), a trailblazer in the biopharmaceutical industry, has achieved a significant milestone with the U.S.…
AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Truqap (capivasertib) in…
Gland Pharma receives USFDA approval for first generic Eribulin Mesylate Injection
In a significant advancement for generic pharmaceuticals, Gland Pharma Limited, a company specializing in generic injectable-focused pharmaceutical products,…
AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US…
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million…
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer…
Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer
Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase…